The primary objective of this study is to evaluate the safety and tolerability of different dose levels of glyburide for injection, administered as a bolus dose followed by a 3-day continuous infusion. The secondary objectives are to assess the pharmacokinetics (PK) of glyburide and blood glucose and serum insulin pharmacodynamic (PD) responses to glyburide.
This study was previously posted by Remedy Pharmaceuticals, Inc. and has since been acquired by Biogen.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
34
Administered as specified in the Treatment Arm.
Administered as specified in the Treatment Arm.
Jasper Clinic
Kalamazoo, Michigan, United States
Number of Participants with Adverse Events and Serious Adverse Events
An adverse event (AE) is defined as any untoward medical occurence such as a sign, symptom, and/or laboratory finding that is concurrent with the use of a drug in humans. A serious adverse event is any AE that is fatal, life-threatening, requires or prolongs hospital stay, results in persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event
Time frame: Up to Day 28
Pharmacokinetic (PK) Parameter of Glyburide: Clearance (CL)
Time frame: Day 1 (baseline) and at multiple time points up to Day 5
PK Parameter of Glyburide: Volume of Distribution (Vz)
Time frame: Day 1 (baseline) and at multiple time points up to Day 5
PK Parameter of Glyburide: Elimination Rate Constant (λz)
Time frame: Day 1 (baseline) and at multiple time points up to Day 5
PK Parameter of Glyburide: Half-Life (t1/2)
Time frame: Day 1 (baseline) and at multiple time points up to Day 5
PK Parameter of Glyburide: Predicted Steady-State Concentration (Css)
Time frame: Day 1 (baseline) and at multiple time points up to Day 5
PK Paramater of Metabolites (M1 and M2): Maximum Plasma Concentrations (Cmax)
Time frame: Day 1 (baseline) and at multiple time points up to Day 5
Pharmacodynamic (PD) Parameter of Glyburide: Change from Baseline in Blood Glucose
Time frame: Day 1 (baseline) and at multiple time points up to Day 5
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
PD Parameter of Glyburide: Change from Baseline in Serum Insulin
Time frame: Day 1 (baseline) and at multiple time points up to Day 5